12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tasimelteon: Development discontinued

Vanda discontinued development of tasimelteon to treat MDD after the double-blind, U.S. Phase IIb/III MAGELLAN trial in 507 patients with MDD showed that once-daily 20 mg tasimelteon missed the primary endpoint of reducing HAMD-17 scores from baseline to week 8 vs. placebo. Specifically, tasimelteon and...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >